Zimmer mobile bearing knee
This article was originally published in The Gray Sheet
Orthopedic implant maker gains PMA approval for its NexGen LPS-Flex mobile bearing knee Dec. 10, setting the stage for a limited market release in January. The device should be available throughout the United States by mid-2008, according to the company. Johnson & Johnson/DePuy is the only other firm to have received PMA approval for mobile bearing knees. In contrast to traditional artificial knees, the polyethylene articulating surface of mobile bearing knees is "free to rotate slightly along with the patient's natural movement," Zimmer explains. LPS-Flex facilitates minimally invasive placement and "when used with the LPS-Flex femoral component ... is designed to safely accommodate active deep flexion of up to 155 degrees." FDA notes that Zimmer will conduct a 10-year postapproval study to evaluate long-term safety and effectiveness
You may also be interested in...
Stryker knee IDE study: Firm will not pursue FDA approval and commercialization of a mobile bearing knee after results of a pivotal study showed no difference in clinical outcomes between the device and traditional fixed bearing knees, Stryker reports March 8 at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans. The company will instead continue to focus on marketing its Triathalon knee system with X3 advanced bearing technology, which has a lower risk of revision than mobile knee systems, Stryker says. According to Millennium Research Group's "U.S. Markets for Large-Joint Reconstructive Implants 2009" report, mobile bearing knees account for about 15% of the total domestic knee arthroplasty market, while fixed bearing knees account for roughly 85%. Johnson & Johnson/DePuy was first to market with its LCS Complete RPM Flexion Knee in 2004, and FDA approved Zimmer's NexGen LPS-Flex mobile bearing knee system in 2007 (1"The Gray Sheet" Dec. 17, 2007)
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.